

## INPOG Executive

Dr Sameer Bakhshi  
 Dr Amita Trehan  
 Dr Brijesh Arora  
 Dr. Nitin Shah  
 Dr Deepak Bansal  
 Dr Tulika Seth  
 Dr Venkatraman Radhakrishnan  
 Dr Ramandeep Singh Arora

## Subcommittee Chairs

ALL	Prof V Saha
AML	Dr S Bakhshi
HL	Dr J Chandra
NHL	Dr A Trehan
ChMyelop	Dr D Bansal
CNS	Dr G Chinnaswamy
Renal	Dr S Agarwala
Neuroblastoma	Dr SP Yadav
Liver	Dr Priyakumari
Retino	Dr AC Mallipatna
STS	Dr S Laskar
PNET	Dr B Biswas
Osteo	Dr T Vora
GCT	Dr V Radhakrishnan
Histiocytosis	Dr G Narula
Epithelial	Dr M Prasad
HSCT	Dr S Bhat
Supportive	Dr B Arora
Acc/Ab	Mrs S Jatia
Epidem	Dr RS Arora
Late Effects	Dr G Kapoor

## Dear InPOG members,

Our mission is to *“To improve the outcomes of children with cancer in India by collaborative research.”* If the activities and discussions of the last few months can be used as an indicator, there is an enormous interest among many of us to be part of this. Consequently, as reported last time, two trials have registered with InPOG. **We are now pleased to report that the InPOG-HL-15-01 is currently recruiting in 4 centres, with several others in the process of obtaining ethical approval. Three patients have been recruited till date.** These are but small, initial steps but they are also purposeful and well planned. Every quarter we will bring you updates on how these trials are progressing as well as the new trials registering.

In the coming months there are many conferences of interest and we would like to flag up three of them.

**The 47<sup>th</sup> annual congress of SIOP is from 8<sup>th</sup>-11<sup>th</sup> October in Cape Town.** As always there is likely to be a sizeable Indian contingent. 142 (13.6%) out of the 1044 abstracts at SIOP this year are from India including 25 oral presentations, 21 poster discussion, and 96 posters.

There are two presentations related to InPOG

- Indian Pediatric Oncology Group - An Initiative of the Pediatric Hematology Oncology Chapter of Indian Academy of Pediatrics - Oral Presentation
- A Collaborative Protocol for Newly Diagnosed Indian childhood Hodgkin Lymphoma Patients - Poster Presentation

**Fifth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin's Lymphoma scheduled for 21<sup>st</sup>-24<sup>th</sup> October, 2015. Italy.**

Early bird registration deadline has been extended to September 30, 2015

**Later in November from the 20<sup>th</sup>-22<sup>nd</sup>, we will have the 19<sup>th</sup> annual conference on the PHO Chapter of IAP (PHOCON) in Pune.**

It promises to be an exciting meeting. **On the afternoon of the 20<sup>th</sup> of November, there will be a 3 hour session dedicated to InPOG with updates from each of the study groups.** Details will be sent via email in next 4 weeks.

## InPOG Registrations

As of 18/09/2015 InPOG has 72 Regular and 32 Associate members.

### Update on Current InPOG Trials

#### **InPOG-HL-15-01 (A collaborative study for newly diagnosed childhood Hodgkin's lymphoma patients in India)**

Principal Investigator	Prof Jagdish Chandra
Registered with InPOG	June 2015
Recruitment commenced	August 2015
Currently patients recruited	3
Currently recruiting centres	Indraprastha Apollo Hospital, New Delhi Institute Rotary Cancer Hospital, AIIMS, New Delhi Max Super-Specialty Hospital, New Delhi Rajiv Gandhi Cancer Institute, New Delhi Sir Ganga Ram Hospital, New Delhi

#### **InPOG-ALL-15-01 (An Indian Childhood Collaborative Leukaemia Group multicentre national standardisation study for newly diagnosed acute lymphoblastic leukaemia)**

Principal Investigator	Prof Vaskar Saha
Registered with InPOG	July 2015
Recruitment commenced	Not yet
Currently patients recruited	NA
Currently recruiting centres	NA

### New important facts to note related to clinical trials

Ministry of Health & Family Welfare has recently released The Drugs & Cosmetics (5<sup>th</sup> amendment) Rules, 2015 published as GSR no. 611(E) on 31<sup>st</sup> July, 2015, in the Gazette of India.

**The said amendment modifies the requirement of Audio-Visual Recording of the Informed Consent Process during Clinical Trials as below:**

*"An audio - video recording of the informed consent process in case of vulnerable subjects in clinical trials of New Chemical Entity or New Molecular Entity including procedure of providing information to the subject and his understanding on such consent, shall be maintained by the investigator for record. Provided that in case of clinical trial of anti-HIV and anti-Leprosy drugs, only audio recording of the informed consent process of individual subject including the procedure of providing information to the subject and his understanding on such consent shall be maintained by the investigator for record."*